Disclosed herein are modified C-terminal fragments of FGF21 optimized for binding to Klotho or antagonizing FGF21 activity. FGF21 peptides modified to comprise modifications to the C-terminal amino acid sequence are disclosed that have enhanced activity at the FGF21 receptor. Additionally, conjugates formed between the optimized FGF21 peptide fragments and insulin like peptides or nuclear hormone receptor ligands are provided.

The present invention relates to novel peptides derived from Kita-kyushu lung cancer antigen (CT83), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.

The present invention relates to novel peptides derived from Kita-kyushu lung cancer antigen (CT83), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.

The present invention discloses a method for treating or/and preventing calcium deficiency-related diseases, which comprises administering a composition containing an effective amount of a peptide to a subject, wherein the peptide has an amino acid sequence as shown in SEQ ID NO. 3. The calcium ions are allowed to bind to the peptide and enter the cells of the patient, to achieve the effect of treating or/and preventing calcium deficiency-related diseases.

The present invention discloses a method for treating or/and preventing calcium deficiency-related diseases, which comprises administering a composition containing an effective amount of a peptide to a subject, wherein the peptide has an amino acid sequence as shown in SEQ ID NO. 3. The calcium ions are allowed to bind to the peptide and enter the cells of the patient, to achieve the effect of treating or/and preventing calcium deficiency-related diseases.

The present invention relates to the field of probiotic adjuvantization of anticancer treatments. In particular, the present invention concerns immunogenic sequences from a prophage present in bacteria identified as efficient adjuvants of cancer treatments. The invention provides bacterial compositions expressing immunogenic sequences from this prophage, immunogenic compositions comprising such sequences and methods using sequences from this prophage, for increasing the anticancer armamentarium.

The invention relates to a food supplement comprising at least the amino acids leucine, isoleucine, valine, threonine and lysine and Chromium. The invention further relates to food compositions comprising the food supplement as well as uses of both.

The invention relates to a food supplement comprising at least the amino acids leucine, isoleucine, valine, threonine and lysine and Chromium. The invention further relates to food compositions comprising the food supplement as well as uses of both.

The invention relates to a food supplement comprising at least the amino acids leucine, isoleucine, valine, threonine and lysine and Chromium. The invention further relates to food compositions comprising the food supplement as well as uses of both.

Disclosed is a method for the treatment of AD, wherein an immune stimulating pharmaceutical composition comprising an aluminium salt is administered to a patient having AD or having a risk to develop AD in an effective amount.